NuPathe Inc. to Report Third Quarter 2010 Results and Hold Conference Call on Thursday, November 11, 2010

CONSHOHOCKEN, PA--(Marketwire - November 04, 2010) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, will report third quarter 2010 results on Thursday, November 11, 2010 after the close of the U.S. financial markets. NuPathe will also host a conference call at 4:30 p.m. EST on the same day to discuss the third quarter 2010 financial results and recent operational highlights. A question and answer session will follow NuPathe's remarks.

To participate on the live call, please dial 800-946-0708 (domestic) or +1-719-457-2601 (international), and provide the participant passcode 2414913 five to ten minutes ahead of the start of the call. A replay of the call will be available for one month within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 2414913.

A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on NuPathe's website for one month following the call.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.